Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive primary membranous nephropathy.
about
Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive primary membranous nephropathy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Peptide GAM immunoadsorption t ...... rimary membranous nephropathy.
@en
Peptide GAM immunoadsorption therapy in primary membranous nephropathy
@nl
type
label
Peptide GAM immunoadsorption t ...... rimary membranous nephropathy.
@en
Peptide GAM immunoadsorption therapy in primary membranous nephropathy
@nl
prefLabel
Peptide GAM immunoadsorption t ...... rimary membranous nephropathy.
@en
Peptide GAM immunoadsorption therapy in primary membranous nephropathy
@nl
P2093
P2860
P356
P1476
Peptide GAM immunoadsorption t ...... primary membranous nephropathy
@en
P2093
Dieter Kramer
Durga Kanigicherla
Moritz Fischer
Paul Brenchley
Prasanna Hanumapura
Sandip Mitra
P2860
P304
P356
10.1002/JCA.21599
P50
P577
2017-11-02T00:00:00Z